Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Beclin 2 negatively regulates innate immune signaling and tumor development
Motao Zhu, … , Guangjun Nie, Rong-Fu Wang
Motao Zhu, … , Guangjun Nie, Rong-Fu Wang
Published August 31, 2020
Citation Information: J Clin Invest. 2020;130(10):5349-5369. https://doi.org/10.1172/JCI133283.
View: Text | PDF
Research Article Cell biology Inflammation

Beclin 2 negatively regulates innate immune signaling and tumor development

  • Text
  • PDF
Abstract

Beclin 2 plays a critical role in metabolic regulation and obesity, but its functions in innate immune signaling and cancer development remain largely unknown. Here, we identified Beclin 2 as a critical negative regulator of inflammation and lymphoma development. Mice with homozygous ablation of BCL2-interacting protein 2 (Becn2) developed splenomegaly and lymphadenopathy and markedly increased ERK1/2 and NF-κB signaling for proinflammatory cytokine production. Beclin 2 targeted the key signaling kinases MEKK3 and TAK1 for degradation through an ATG9A-dependent, but ATG16L/Beclin 1/LC3–independent, autophagic pathway. Mechanistically, Beclin 2 recruited MEKK3 or TAK1 through ATG9A to form a complex (Beclin 2-ATG9A-MEKK3) on ATG9A+ vesicles upon ULK1 activation. Beclin 2 further interacted with STX5 and STX6 to promote the fusion of MEKK3- or TAK1-associated ATG9A+ vesicles to phagophores for subsequent degradation. Importantly, Becn2-deficient mice had a markedly increased incidence of lymphoma development, with persistent STAT3 activation. Myeloid-specific ablation of MEKK3 (Map3k3) completely rescued the phenotypes (splenomegaly, higher amounts of proinflammatory cytokines, and cancer incidence) of Becn2-deficient mice. Hence, our findings have identified an important role of Beclin 2 in the negative regulation of innate immune signaling and tumor development through an ATG9A-dependent, but ATG16L/Beclin 1/LC3–independent, autophagic pathway, thus providing a potential target for the treatment of inflammatory diseases and cancer.

Authors

Motao Zhu, Guangtong Deng, Peng Tan, Changsheng Xing, Cuiping Guan, Chongming Jiang, Yinlong Zhang, Bo Ning, Chaoran Li, Bingnan Yin, Kaifu Chen, Yuliang Zhao, Helen Y. Wang, Beth Levine, Guangjun Nie, Rong-Fu Wang

×

Figure 6

Beclin 2 mediates the degradation of TAK1 and MEKK3 through an ATG9A- and ULK-dependent autophagic pathway.

Options: View larger image (or click on image) Download as PowerPoint
Beclin 2 mediates the degradation of TAK1 and MEKK3 through an ATG9A- an...
(A and B) WT 293T cells, sgRNA-guided ATG9A-KO 293T cells (A), and sgRNA-guided ULK1-KO 293T cells (B) were transfected with HA-TAK1 or HA-MEKK3 alone or together with Flag–Beclin 2 plasmid, followed by immunoblotting with the indicated antibodies. Blots were run contemporaneously with the same protein samples (A). Bottom panels: quantitative analysis of HA-TAK1 and HA-MEKK3 expression and degradation percentages in WT and KO cells after normalization based on band intensity of 3 independent experiments. (C and D) WT and ATG9A-KO (C) or ULK1-KO (D) 293T cells were transfected with the HA–Beclin 2 plasmid alone or together with Flag-MEKK3. Cell lysates were immunoprecipitated using anti-Flag beads, followed by immunoblotting with the indicated antibodies. Data are representative of 3 independent experiments. (E) Confocal images of WT, ATG9A-KO, and ULK1-KO 293T cells cotransfected with GFP-MEKK3 and Flag–Beclin 2, then stained with anti-Flag antibody, followed by Alexa Fluor 633–conjugated secondary antibody staining. Hoechst 33342 was applied for nucleus staining. Scale bars: 10 μm. (F) Confocal images of WT, ATG9A-KO, and ULK1-KO 293T cells transfected with GFP-MEKK3, then stained with lysotracker and Hoechst 33342. Scale bars: 10 μm. Original magnification, ×1000 (merge); ×2500 (magnified). Data are plotted as mean ± SEM. Pearson’s correlation coefficient for colocalization shown in E and F was used with Image J Coloc 2 (at least 30 cells were analyzed per condition)\. Statistical differences between EmpVec-transfected and Flag–Beclin 2–transfected cells were calculated using Student’s unpaired t test (A and B). Statistical differences between WT and KO groups were calculated using Student’s unpaired t test (A) or 1-way ANOVA with Dunnett’s multiple comparison tests (B, E, and F). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts